The historical rank and industry rank for Shanghai Obio Technology (Group)'s FCF Margin % or its related term are showing as below:
SHSE:688238'
s FCF Margin % Range Over the Past 10 Years
Min: -311.15 Med: -92.93 Max: -23.54
Current: -73.07
During the past 12 years, the highest FCF Margin % of Shanghai Obio Technology (Group) was -23.54%. The lowest was -311.15%. And the median was -92.93%.
SHSE:688238's FCF Margin % is ranked better than 51.31% of 957
companies
in the Biotechnology industry
Industry Median: -84.65
vs SHSE:688238: -73.07
Shanghai Obio Technology (Group) FCF Margin % Related Terms
Shanghai Obio Technology (Group) FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688238 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Shanghai Obio Technology (Group)'s FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Obio Technology (Group) FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Obio Technology (Group)'s FCF Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai Obio Technology (Group)'s FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Obio Technology (Group) (SHSE:688238) has a FCF Margin % of -193.37% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shanghai Obio Technology (Group) and its competitors. According to the industry distribution chart, Shanghai Obio Technology (Group) ranks #466 out of 957 companies in the Biotechnology industry, placing it in the top 48.7%.
Is Shanghai Obio Technology (Group)'s FCF Margin % too high?
Shanghai Obio Technology (Group)'s current FCF Margin % is -193.37%. Based on the distribution chart, Shanghai Obio Technology (Group) ranks #466 out of 957 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Obio Technology (Group) has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Obio Technology (Group)'s FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Obio Technology (Group) ranks #466 out of 957 companies for FCF Margin %. This puts Shanghai Obio Technology (Group) in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shanghai Obio Technology (Group) and its competitors. Shanghai Obio Technology (Group)'s current FCF Margin % is -193.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Obio Technology (Group) stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Obio Technology (Group) (SHSE:688238) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.77, compared to a current price of ¥5.48 — trading 29.5% below its estimated fair value. The current FCF Margin % is -193.37%. Shanghai Obio Technology (Group)'s overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Shanghai Obio Technology (Group) (SHSE:688238), the current FCF Margin % is -193.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Obio Technology (Group) (SHSE:688238) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Obio Technology (Group) stock appears to be undervalued.
The current stock price of ¥5.48 is trading 29.5% below its estimated GF Value™ of ¥7.77.
GuruFocus considers Shanghai Obio Technology (Group) to be Modestly Undervalued.
Key valuation signals for SHSE:688238:
FCF Margin %: -193.37%
GF Value™: ¥7.77 vs. price of ¥5.48 (29.5% below fair value)
No single metric tells the full story. See the SHSE:688238 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Obio Technology (Group) Business Description
Shanghai Obio Technology (Group) Corp Ltd provides contract research organization (CRO) services, including gene therapy vector development and gene function research for basic research, as well as contract development and manufacturing organization (CDMO) services, including IND-enabling CMC research and GMP production of clinical samples for gene therapy drug development.
63GF Score
Get the complete analysis for SHSE:688238
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688238 has been successfully added to your 
